TITLE

Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial

AUTHOR(S)
A J Flammer
PUB. DATE
March 2009
SOURCE
Heart;Mar2009, Vol. 95 Issue 5, p385
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: Impaired endothelial function was demonstrated in HIV-infected persons on protease inhibitor (PI)-containing antiretroviral therapy, probably due to altered lipid metabolism. Atazanavir is a PI causing less atherogenic lipoprotein changes. This study determined whether endothelial function improves after switching from other PI to atazanavir. DESIGN: Randomised, observer-blind, treatment-controlled trial. SETTING: Three university-based outpatient clinics. PATIENTS: 39 HIV-infected persons with suppressed viral replication on PI-containing regimens and fasting low-density lipoprotein (LDL)-cholesterol greater than 3 mmol/l. INTERVENTION: Patients were randomly assigned to continue the current PI or change to unboosted atazanavir. MAIN OUTCOME MEASURES: Endpoints at week 24 were endothelial function assessed by flow-mediated dilation (FMD) of the brachial artery, lipid profiles and serum inflammation and oxidative stress parameters. RESULTS: Baseline characteristics and mean FMD values of the two treatment groups were comparable (3.9% (SD 1.8) on atazanavir versus 4.0% (SD 1.5) in controls). After 24 weeks’ treatment, FMD decreased to 3.3% (SD 1.4) and 3.4% (SD 1.7), respectively (all p = ns). Total cholesterol improved in both groups (p<0.0001 and p = 0.01, respectively) but changes were more pronounced on atazanavir (p = 0.05, changes between groups). High-density lipoprotein and triglyceride levels improved on atazanavir (p = 0.03 and p = 0.003, respectively) but not in controls. Serum inflammatory and oxidative stress parameters did not change; oxidised LDL improved significantly in the atazanavir group. CONCLUSIONS: The switch from another PI to atazanavir in treatment-experienced patients did not result in improvement of endothelial function despite significantly improved serum lipids. Atherogenic lipid profiles and direct effects of antiretroviral drugs on the endothelium may affect vascular function. TRIAL REGISTRATION NUMBER: NCT00447070.
ACCESSION #
36532608

 

Related Articles

  • Selenium, Selenoenzymes, Oxidative Stress and Risk of Neoplastic Progression from Barrett's Esophagus: Results from Biomarkers and Genetic Variants. Takata, Yumie; Kristal, Alan R.; Santella, Regina M.; King, Irena B.; Duggan, David J.; Lampe, Johanna W.; Rayman, Margaret P.; Blount, Patricia L.; Reid, Brian J.; Vaughan, Thomas L.; Peters, Ulrike // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

    Clinical trials have suggested a protective effect of selenium supplementation on the risk of esophageal cancer, which may be mediated through the antioxidant activity of selenoenzymes. We investigated whether serum selenium concentrations, selenoenzyme activity, oxidative stress and genetic...

  • The sixteen-year trend of syphilis in Turkey: data from blood donors. Oncul, Oral; Emekdas, Gurol; Cavuslu, Saban; Artuk, Cigdem; Aksoy, Ali // Tropical Doctor;Jul2008, Vol. 38 Issue 3, p181 

    This study was conducted in order to determine the prevalence and trends of antibodies to syphilis among Turkish blood donors (BDs) at the 22 National Blood Transfusion Service, Kizilay, between 1989 and 2004. Among the 6,240,130 BDs, a reactive result was obtained with the rapid plasma reagin...

  • CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants. Pohlmeyer, Christopher W.; Buckheit, Robert W.; Siliciano, Robert F.; Blankson, Joel N. // Retrovirology;2013, Vol. 10 Issue 1, preceding p1 

    Background Elite Controllers or Suppressors (ES) are HIV-1 positive individuals who maintain plasma viral loads below the limit of detection of standard clinical assays without antiretroviral therapy. Multiple lines of evidence suggest that the control of viral replication in these patients is...

  • Lopinavir/ritonavir concentrations not linked to lipid abnormalities?  // Reactions Weekly;5/1/2004, Issue 999, p5 

    Discuses research being done on the association of lipid levels in HIV-infected patients with lopinavir and ritonavir plasma concentrations. Reference to a study by C. Torti et al published in the March 2004 issue of the "Journal of Acquired Immune Deficiency Syndromes"; Drug dosage...

  • Characterization of V1/V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals. Krachmarov, C.; Revesz, K.; Prattipati, R.; Reichman, C.; Li, B.; Derdeyn, C.; Sarlo, J.; Zingman, B.; Honnen, W.; Pinter, A. // Retrovirology;2012 Supplement, Vol. 9 Issue Suppl 2, p1 

    An abstract of the research paper "Characterization of V1/V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals," by C. Krachmarov and colleagues is presented.

  • CSF REPLICATION REDUCED WITH SUSTIVA.  // AIDS Patient Care & STDs;Oct98, Vol. 12 Issue 10, p802 

    Reports on the reduction in HIV-RNA levels in plasma and cerebrospinal fluid (CSF) of HIV-infected patients who took Sustiva `efavirenz,' in combination with either AZT and 3TC. Measurement of the patients' CSF and HIV-RNA drug levels; Details on the patients' treatment with Sustiva.

  • Durable HIV Treatment Benefit Despite Low-Level Viremia. Deeks, Steven G. // JAMA: Journal of the American Medical Association;7/11/2001, Vol. 286 Issue 2, p224 

    Editorial. Discusses the treatment methods for patients with the HIV disease and how this affects their levels of plasma viremia. Mentions two articles in this issue by Hermankova et al and Havlir et al; Implications of their data; Effectiveness of antiretroviral therapy; Assessment of a...

  • Plasma concentrations of soluble Fas receptors (Fas) and Fas ligands (FasL) in relation to CD4+ cell counts in HIV-1 positive and negative patients in Yaounde, Cameroon. Ikomey, George M; Okomo-Assoumou, marie-Claire; Atashlili, Julius; Mesembe, Martha T; Mukwele, Bertha; Lyonga, Emilia; Eyoh, Agnes; Ndumbe, Peter M // BMC Research Notes;2012, Vol. 5 Issue 1, p322 

    Background: Though documented that HIV infection progresses with the depletion of CD4+ cells, the exact mechanisms by which these cell depletions occur are not clearly understood. This study aimed at evaluating the plasma levels of soluble Fas receptors and ligands in HIV-infected and uninfected...

  • Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. Zhang, Jenny; Zhu, Li; Stonier, Michele; Coumbis, John; Xu, Xiaohui; Wu, Yaoshi; Arikan, Dilek; Farajallah, Awny; Bertz, Richard // Journal of Antimicrobial Chemotherapy (JAC);Sep2011, Vol. 66 Issue 9, p2075 

    Objectives Treatment of HIV/tuberculosis (TB) co-infected patients is complex due to drug–drug interactions for these chronic diseases. This study evaluates an intermittent dosing regimen for rifabutin when it is co-administered with ritonavir-boosted atazanavir. Patients and methods A...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics